SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014

被引:0
|
作者
R. Garcia-Carbonero
P. JImenez-Fonseca
A. Teulé
J. Barriuso
I. Sevilla
机构
[1] Hospital Universitario Virgen del Rocio,Medical Oncology Department
[2] Instituto de Biomedicina de Sevilla (IBIS) (Universidad de Sevilla,Medical Oncology Department
[3] CSIC,Medical Oncology Department
[4] HUVR),Faculty of Life Sciences
[5] Center affiliated to the Red Temática de Investigación Cooperativa en Cancer (RTICC),Department of Medical Oncology
[6] Instituto Carlos III,Medical Oncology Department
[7] Spanish Ministry of Science and Innovation,undefined
[8] Hospital Universitario Central de Asturias,undefined
[9] Instituto Catalán de Oncología (ICO),undefined
[10] Barcelona,undefined
[11] Spain,undefined
[12] Center affiliated to the Red Temática de Investigación Cooperativa en Cancer (RTICC),undefined
[13] Instituto Carlos III,undefined
[14] Spanish Ministry of Science and Innovation,undefined
[15] University of Manchester,undefined
[16] The Christie NHS Foundation Trust,undefined
[17] Hospital Universitario Virgen de la Victoria y Hospital Regional Universitario,undefined
来源
Clinical and Translational Oncology | 2014年 / 16卷
关键词
Guidelines; Neuroendocrine tumors; Neuroendocrine neoplasms; Enteropancreatic; Diagnosis; Therapy;
D O I
暂无
中图分类号
学科分类号
摘要
GEP-NENs are a challenging family of tumors of growing incidence and varied clinical management and behavior. Diagnostic techniques have substantially improved over the past decades and significant advances have been achieved in the understanding of the molecular pathways governing tumor initiation and progression. This has already translated into relevant advances in the clinic. This guideline aims to provide practical recommendations for the diagnosis and treatment of GEP-NENs. Diagnostic workup, histological and staging classifications, and the different available therapeutic approaches, including surgery, liver-directed ablative therapies, peptide receptor radionuclide therapy, and systemic hormonal, cytotoxic or targeted therapy, are briefly discussed in this manuscript. Clinical presentation (performance status, comorbidities, tumor-derived symptoms and hormone syndrome in functioning tumors), histological features [tumor differentiation, proliferation rate (Ki-67), and expression of somatostatin receptors], disease localization and extent, and resectability of primary and metastatic disease, are all key issues that shall be taken into consideration to appropriately tailor therapeutic strategies and surveillance of these patients.
引用
收藏
页码:1025 / 1034
页数:9
相关论文
共 50 条
  • [1] SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014
    Garcia-Carbonero, R.
    JImenez-Fonseca, P.
    Teule, A.
    Barriuso, J.
    Sevilla, I.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2014, 16 (12): : 1025 - 1034
  • [2] SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018)
    E. González-Flores
    R. Serrano
    I. Sevilla
    A. Viúdez
    J. Barriuso
    M. Benavent
    J. Capdevila
    P. Jimenez-Fonseca
    C. López
    R. Garcia-Carbonero
    Clinical and Translational Oncology, 2019, 21 : 55 - 63
  • [3] SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018)
    Gonzalez-Flores, E.
    Serrano, R.
    Sevilla, I.
    Viudez, A.
    Barriuso, J.
    Benavent, M.
    Capdevila, J.
    Jimenez-Fonseca, P.
    Lopez, C.
    Garcia-Carbonero, R.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (01): : 55 - 63
  • [4] Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
    Kaliszewski, Krzysztof
    Ludwig, Maksymilian
    Greniuk, Maria
    Mikula, Agnieszka
    Zagorski, Karol
    Rudnicki, Jerzy
    CANCERS, 2022, 14 (08)
  • [5] Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
    Alexandraki, Krystallenia I.
    Daskalakis, Kosmas
    Tsoli, Marina
    Grossman, Ashley B.
    Kaltsas, Gregory A.
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2020, 31 (03): : 239 - 255
  • [6] Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update
    Christo Kole
    Nikolaos Charalampakis
    Michail Vailas
    Maria Tolia
    Maria Sotiropoulou
    Sergios Tsakatikas
    Nikolaos-Iasonas Kouris
    Marina Tsoli
    Anna Koumarianou
    Michalis V. Karamouzis
    Dimitrios Schizas
    Cancer Immunology, Immunotherapy, 2022, 71 : 761 - 768
  • [7] Gastroenteropancreatic neuroendocrine tumors (GEP-NENs)
    Sebesta, Christian
    Feichter, Alexandra
    Selimi, Flonza
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2023, 173 (9-10) : 221 - 226
  • [8] Autophagy flux is induced in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)
    Angelioudaki, I.
    Theochari, M.
    Koniaris, E.
    Kataki, A.
    Stoupis, L.
    Mitrousias, A.
    Tzingounis, A-G.
    Dafnios, N.
    Zografos, G.
    Kafiri, G.
    Konstadoulakis, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S956 - S957
  • [9] Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
    Puccini, Alberto
    Poorman, Kelsey
    Salem, Mohamed E.
    Soldato, Davide
    Seeber, Andreas
    Goldberg, Richard M.
    Shields, Anthony F.
    Xiu, Joanne
    Battaglin, Francesca
    Berger, Martin D.
    Tokunaga, Ryuma
    Naseem, Madiha
    Barzi, Afsaneh
    Iqbal, Syma
    Zhang, Wu
    Soni, Shivani
    Hwang, Jimmy J.
    Philip, Philip A.
    Sciallero, Stefania
    Korn, W. Michael
    Marshall, John L.
    Lenz, Heinz-Josef
    CLINICAL CANCER RESEARCH, 2020, 26 (22) : 5943 - 5951
  • [10] Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update
    Kole, Christo
    Charalampakis, Nikolaos
    Vailas, Michail
    Tolia, Maria
    Sotiropoulou, Maria
    Tsakatikas, Sergios
    Kouris, Nikolaos-Iasonas
    Tsoli, Marina
    Koumarianou, Anna
    Karamouzis, Michalis V.
    Schizas, Dimitrios
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (04) : 761 - 768